ImpriMed, Inc.
ImpriMed uses artificial intelligence and live cancer cell testing to predict how individual dogs with lymphoma or leukemia will respond to specific anticancer drugs before treatment begins. The platform delivers personalized drug response predictions, immune subtyping, and clonality analysis to veterinary oncologists within 3-7 days, with over 25,000 canine and feline lymphoma tests reported to date.
- Healthcare Technology
- Biotechnology
- Pet Technology
- Artificial Intelligence
- Data & Analytics
- Digital Health
- Software Only
Funding
Raised to date
$34.7MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Veterinarians treating dogs with lymphoma face challenges in predicting individual patient responses to various anticancer drugs, leading to potentially ineffective treatments and increased costs. Traditional methods often rely on generalized treatment protocols without considering the unique characteristics of each dog's cancer cells.
Solution
ImpriMed offers an AI-driven platform that analyzes live cancer cells from dogs diagnosed with lymphoma or leukemia to predict their response to specific anticancer drugs. By testing the effectiveness of anticancer therapy drugs directly on a dog's live cancer cells, ImpriMed generates a personalized prediction profile. This profile combines measurements with biological information using artificial intelligence to predict which drugs are most likely to be effective for an individual dog's lymphoma or leukemia. The platform provides oncologists with drug response predictions, immune subtyping, and clonality analysis, enabling informed treatment decisions from the outset. Results are delivered within 3-7 days of sample receipt, allowing treatment plans to be personalized before chemotherapy begins.
Target Audience
Primary customers are veterinary oncologists seeking to improve treatment outcomes for dogs with lymphoma and leukemia through personalized medicine, as well as the pet owners who partner with them in treatment decisions.
Features
- AI-driven analysis of live cancer cells to predict drug response
- Ex vivo drug sensitivity assay measuring live tumor cell response to anticancer drugs
- Machine learning algorithms trained by real-world clinical outcomes from 340+ collaborating hospitals
- Identification of T- or B-cell cancer and likely drug responses
- Graphs comparing average drug responses to individual patient responses
- Clinically validated results published in peer-reviewed scientific journals
- Simple workflow requiring only tumor and blood samples shipped via overnight delivery, with reports returned in 3-7 days